Clinical Trial

Agilisium Achieves AWS Life Sciences Competency Status

LOS ANGELES, July 30, 2024 /PRNewswire/ -- Agilisium, a pioneering leader in Data Analytics, Cloud, and Life Science solutions, today announced…

2 years ago

eClinical Solutions Market worth $22.1 billion by 2029 driven by Rising Chronic Illness Rates | MarketsandMarkets™

CHICAGO, July 30, 2024 /PRNewswire/ -- The global eClinical Solutions Market is expected to grow from USD 11.6 billion in 2024…

2 years ago

Slope Appoints Jim Munz as Chief Product & Technology Officer

Former Veeva and ERT clinical trial technology executive will drive strategy towards a complete, tech-enabled biospecimen lifecycle solution RICHMOND, Va.,…

2 years ago

Next Presentation in Record-Breaking Sleep Apnea Webinar Series Announced

Live presentations by leading sleep researchers available globally to front-line clinicians MURFREESBORO, Tenn., July 30, 2024 /PRNewswire/ -- SleepWorld Magazine…

2 years ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

— HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that Extends Cash Runway Potentially…

2 years ago

Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531

GAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first…

2 years ago

Nascent Biotech Presents at the July Emerging Growth Conference

Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company  NORTH PALM…

2 years ago

PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…

2 years ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to…

2 years ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for…

2 years ago